Skip to main content

Table 1 Clinical characteristics of study subjects

From: Association analysis of ILVBL gene polymorphisms with aspirin-exacerbated respiratory disease in asthma

  ATA AERD P
N 995 141
Sex (male, %) 38.5% 38.3% 0.965
Age (yr) 44.8 ± 0.49 42.39 ± 1.26 0.082
Age of onset (yr) 38.82 ± 0.53 34.5 ± 1.53 0.007
Smoking status (NS/ES/SM, %) 69.6/16.6/13.7 79.4/5.0/15.6 0.002
Body mass index (kg/m2) 24.38 ± 0.11 23.65 ± 0.3 0.023
FEV1 before ASA challenge (% predicted) 83.42 ± 0.63 80.52 ± 1.76 0.124
Decline of FEV1 after ASA challenge (%) 3.83 ± 0.16 32.42 ± 1.08 1.14× 10−53
log(PC20 methacholine (mg/mL)) 0.36 ± 0.02 −0.02 ± 0.07 1.13× 10−7
Atopy (Y, %) 51.9% 48.2% 0.419
Serum total IgE (kU/L) 393.02 ± 20.22 411.2 ± 60.71 0.768
Urticaria (Y, %) 22.0% 19.9% 0.562
Water’s view (Y, %) 34.7% 59.6% 1.14× 10−8
Peripheral eosinophil count 119.88 ± 4.72 112.2 ± 13.97 0.603
Sputum eosinophil (%) 33.37 ± 1.26 32.65 ± 3.83 0.858
Sputum neutrophil (%) 5.66 ± 0.51 11.35 ± 2.31 0.018
  1. ATA aspirin tolerant asthmatics, AERD aspirin-exacerbated respiratory disease, NS never smokers, ES ex-smokers, SM current smokers
  2. Numeric data were presented as mean ± standard error
  3. P values were obtained using independent t-test or χ2 test